Prolonged Metabolic Correction in Adult Ornithine Transcarbamylase-deficient Mice with Adenoviral Vectors*

(Received for publication, September 19, 1995, and in revised form, November 22, 1995)

Xuehai Ye†, Michael B. Robinson§¶, Mark L. Batshaw§¶, Emma E. Furth**, Ian Smith§¶, and James M. Wilson‡‡

From the Institute for Human Gene Therapy and Departments of Molecular and Cellular Engineering and Medicine of the University of Pennsylvania and Wistar Institute, Philadelphia, Pennsylvania 19104, the Department of Pediatrics, Department of Pathology and Laboratory Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania 19104, and Children's Seashore House and Children's Hospital, Philadelphia, Pennsylvania 19104

A murine model of ornithine transcarbamylase (OTC) deficiency was used in this study to evaluate the efficacy of recombinant adenoviruses for correcting the metabolic defect in liver. Recombinant adenoviruses deleted in E1 and containing a human OTC cDNA expressed little functional OTC enzyme in vivo and had no observable impact on the underlying metabolic abnormalities of the OTC-deficient mouse (i.e., elevated urinary orotate and serum glutamine). E1-deleted vectors were improved through the use of the strong constitutive promoter from cytomegalovirus driving the normal murine homolog of OTC cDNA and the ablation of E2a with a temperature-sensitive mutation. Infusion of this improved vector into the mouse model was associated with a complete normalization of liver OTC enzyme activity that persisted for at least 2 months with complete but transient correction in serum glutamine and urine orotic acid. These studies illustrate the utility of improved adenoviral vectors in the treatment of liver metabolic disease.

A deficiency of ornithine transcarbamylase (OTC) is associated with derangements in nitrogen metabolism leading to hyperammonemic encephalopathy in humans. This X-linked recessive disorder is the most common inborn error of urea synthesis, with an estimated prevalence of 1:40,000 to 1:80,000 births (1). Approximately one-half of affected males develop marked elevations of ammonia leading to coma in the 1st week of life. These episodes are associated with 50% mortality (2). Survivors of the neonatal crisis often experience recurrent episodes of potentially life-threatening hyperammonemia that are precipitated by excessive protein intake or catabolic stress (3). Since the urea cycle is principally localized to the liver, gene therapy directed to hepatocytes has the potential to correct the underlying metabolic derangements. The success of orthotopic liver transplantation in this disease indicates that hepatocyte-directed gene transfer should be sufficient for metabolic correction (4–6).

Muirne models of OTC deficiency are available for the development and evaluation of in vivo liver-directed gene therapies. The best characterized model is the sparse fur (spf) mouse, in which a missense mutation in exon 117 of the OTC gene leads to a functionally defective enzyme with hepatic OTC activity reduced to approximately 5–20% of wild-type levels at physiologic pH (7, 8). The other mutant is the spf asd (abnormal skin and hair) mouse, in which a point mutation in the final base of exon 4 of the OTC gene leads to aberrant splicing with markedly reduced levels of OTC mRNA and only 5% of normal OTC activity (9, 10). In these two mouse strains, hemizygous male and homozygous female pups are runted and have wrinkled skin with little to no fur early in development. On a normal diet, adult spf or spf asd hemizygous develop symptomatic hyperammonemia, glutaminemia and severe orotic aciduria (8, 9), essentially identical with the findings in affected humans. They also have a markedly shortened lifespan and behavioral and learning abnormalities (11).

Recombinant adenoviruses have been evaluated as vectors for liver-directed gene therapy in a variety of metabolic disorders including OTC deficiency (12–15). Adenovirus is rendered defective for use as a vector by deleting the immediate early genes E1a and E1b and incorporating a minigene expressing the therapeutic protein. Adenovirus is efficiently targeted to hepatocytes in vivo following intravenous infusion; high level transgene expression can be achieved in virtually 100% of hepatocytes, most of which are fully differentiated and not dividing. The first use of E1-deleted viruses for gene therapy was in newborn spf asd mice (14). Infusion of a vector containing a rat OTC cDNA into the newborn animals led to an increase in hepatic OTC activity in 4/15 mice which persisted for 1–2 months and was associated with decreased urinary orotic acid excretion.

Experiments of adenovirus-mediated gene transfer to liver have not been as encouraging when performed in other species or in adult mice. Gene transfer to liver is similarly efficient in these experimental models; however, transgene expression is transient, often lasting less than 14–21 days, and associated with substantial hepatitis (13, 16–18). We believe this is due, in part, to destructive cellular immune responses to the genetically corrected hepatocytes of the adult animal. This does not occur in the newborn mouse, who is exposed to gene therapy prior to immunologic maturity when tolerance can be induced. Deletion of E1a and E1b is insufficient to prevent either expression of other viral genes or actual replication at high multiplicities of infection (18, 19). A concerted immune response to exogenous and endogenously produced viral protein (or trans-
Metabolic Correction of OTC Deficiency in spf Mice

Gene product ensues. This results in activation of both CD4 (T helper) and CD8 (cytotoxic T) lymphocytes against the virus-infected cell and extinction of transgene expression by either destruction of the cell or through other indirect mechanisms (18, 20). This is particularly problematic for treatment of humans when the window for inducing tolerance is in the prenatal period of 14–18 weeks gestation (21).

We describe in this report the use of adenoviral vectors for treatment of OTC deficiency in the previously described murine models of the human disease. Use of a sufficiently strong promoter with a species homologous OTC cDNA was important in achieving curative therapeutic gene expression. An E1-deleted adenoviral vector, made temperature-sensitive in the E2a gene, normalized hepatic activity of OTC in the E2a gene, normalized hepatic activity of OTC in the spf mouse and completely corrected metabolic abnormalities in urinary orotate and serum glutamine.

**EXPERIMENTAL PROCEDURES**

Animals—The mouse strains spf, spf<sup>ash</sup>, and C3HeB/J were purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained in a specific pathogen-free facility. Female spf and C3HeB/J mice were bred with normal male (xy) C3HeB/J mice to generate experimental spf or spf<sup>ash</sup>/y mice. All animals used in the experiment were between 6 and 10 weeks of age.

Construction and Propagation of the First and the Second Generation Recombinant Adenoviruses—A summary of recombinant adenoviruses used in this study is provided in Fig. 1. Nomenclature used for naming the recombinants described in this paper is E2a renaming of the adenoviral vector, designation of the adenoviral late gene products was performed as described by Kozarsky et al. (24). The new plasmid, designated H5.010CB<sub>hOTC</sub>, was derived from a retrotroviral vector containing a human OTC minigene. The coding sequence for human OTC was removed from plasmid pHO-731 on a 1.0-kilobase HindIII fragment (22), blunted with Klenow, ligated with BglII linkers, and cloned in direct orientation into the BamHI site of the retrotroviral vector pRAd322 (23). A BglII restriction fragment from this vector containing the chicken β-actin promoter, human OTC cDNA, 3′-untranslated sequences including 130 base pairs of retrotroviral sequence was cloned in place of lacZ in the adenoviral vector pAd.CMV-lacZ (13). This new plasmid, called pAd.CBH<sub>hOTC</sub>, expresses human OTC cDNA from a CMV-enhanced β-actin promoter and is deleted of adenoviral sequences spanning 1 to 9.6 map units. In preparation for production of virus, pAd.CBH<sub>hOTC</sub> was linearized with NheI and transfected into 293 cells with Clal/XbaI-restricted sub360 genomic DNA, which contains a substitution of sequence in E3b, which differs from the EC3b vector (Promega), and restricted with Spel and SadI. A 1.5-kilobase fragment containing mouse cDNA was isolated, blunted, and cloned into the EcoRV site of an adenoviral vector pAd.CMV-link (a CMV promoter-polylinker cassette was cloned into a plasmid containing the adenoviral sequences 0 to 16 map units deleted of E1a and E1b as described in the other adenovirus vectors). The new plasmid, designated pAd.CMV<sub>hOTC</sub>, was linearized with EcoRI and cotransfected into 293 cells with Clal/XbaI-restricted sub360 or sub360/ts125 DNA. The resulting recombinant virus (H5.010CMV<sub>hOTC</sub> or H5.110CMV<sub>hOTC</sub>) was purified through three rounds of plaque isolation. The integrity of the murine OTC cDNA was confirmed by DNA sequence analysis.

OTC Lysate Assay—Cells were harvested by scraping into mitochondria lysis buffer (0.5% Triton, 10 mM Hepes, pH 7.4, 2 mM diethiothreitol), and total protein was extracted by three freeze-thaw cycles. Liver tissue was homogenized in mitochondria lysis buffer with a Polytron homogenizer. The homogenate was centrifuged in a Microfuge at the maximum speed for 5 min, the supernatant was transferred to a new tube, and OTC enzyme activity was measured as described by Lee and Nussbaum (26) with modifications. Briefly, 2–10 µg of total cellular protein was added to 700 µl of reaction mixture (5 mM ornithine, 15 mM carbamyl phosphate, and 270 mM triethanolamine, pH 7.7) which was incubated at 37°C for 30 min. Reactions were stopped by adding 250 µl of 3:1 phosphoric acid/sulfuric acid (by volume). Citrulline production was then determined by adding 50 µl of 3% 2,3-butanedione monoxime, incubating at 95–100°C in the dark for 15 min, and measuring absorbance at 490 nm.

OTC Histology—Slides of liver tissue, less than 3 mm thick, were fixed in 4% paraformaldehyde in PBS for 4–6 h at room temperature and subsequently washed with PBS containing 10% sucrose for 2 h, PBS containing 20% sucrose for 2 h, and finally PBS containing 30% sucrose overnight. The liver slides were dehydrated, xylene- and sectioned for histochemical staining as described by Mizutani (27). Briefly, a reaction medium was prepared first, which contained 12 mg of carbamyl phosphate, lithium salt; 20 mg of l-ornithine dihydrochloride, 3.2 g of sucrose; 20 ml of 0.05 M triethanolamine buffer, pH 7.2; 16 ml of distilled water, and 4 ml of 1% lead nitrate. The lead nitrate solution was then added dropwise with continuous stirring, and the solution was readjusted to pH 7.2 with 1 N NaOH. The slightly turbid substrate mixture was filtered and used immediately. Sections were incubated for 30 min in reaction medium at room temperature, washed with distilled water three times, immersed in 0.37% ammonium sulfide for 1 min, rinsed with distilled water again, and mounted for light microscopic observations. The dark brown deposits of lead sulfide indicated the sites of OTC activity.

RNA Hybridization Analyses—Total cellular RNA was isolated, fractionated on formaldehyde gel, and transferred onto Hybond-N nylon filters (Amersham). DNA fragments used as probes in RNA hybridizations were gel-purified and labeled with (γ-32P)ATP by random priming.

In Vivo Delivery of Recombinant Adenoviruses to Mouse Liver—spf, spf<sup>ash</sup>/y, and male C3HeB/J mice at 6–10 weeks of age were used in this study. Blood samples were collected by retro-orbital bleeding the day before the experiment (day −1). Urine samples were collected at day −3 and day −1. On day 0, virus suspended in 0.1 ml of phosphate-buffered saline (PBS) was administered to animals via the tail vein. Urine and plasma samples were collected at weekly intervals after viral infusion. The animals were sacrificed at day 4, 7, 14, or 28, depending on the experimental protocol. Liver tissues were prepared for histochemical, biochemical, and molecular biological analysis.

Immunocytochemical Analysis—Immunofluorescence staining of adenoviral late gene products was performed as described by Kozarsky et al. (13). The primary antibody was a polyclonal rabbit antibody specific to Ad5 late gene products (produced in Dr. Wilson’s laboratory). The secondary antibody was a fluorescein isothiocyanate-labeled goat anti-rabbit 1gG (Chemicon, Temecula, CA).

Determination of Urinary Orotate—Mouse urine was collected at day −3, day −1, and at different time points after virus infusion by leaving the animals in a metabolic cage overnight. Urinary orotate levels were measured in duplicate for each sample according to Brusilow et al. (28).

Determination of Plasma Amino Acids—Plasma amino acids were analyzed by precolumn derivatization with o-phthalaldehydes as described previously by Robinson et al. (29). After centrifugation of heparinized blood, an aliquot of plasma was derivatized with a DNA-binding reagent to an equal volume of 0.8 N perchloric acid which contained the internal standards L-α-aminoacidipate and L-α-amino-α-butyrice. After centrifugation, an aliquot of the supernatants was neutralized with 2 µl KCO<sub>3</sub>. These samples were derivatized using an Autosampler. External standards were injected after every fifth specimen.

Evaluation of Liver Pathology—Histopathology was evaluated using the criteria developed by Knodell et al. (30). The three criteria scored were: I, periportal and bridging necrosis; II, intralobular degeneration and focal necrosis; and III, portal inflammation. Analyses were performed on three to four animals per time point.

**RESULTS AND DISCUSSION**

Ineffective Genetic Reconstitution in spf Mice Using Adenoviral Vectors Containing Human OTC—The spf and spf<sup>ash</sup> mice are well described animal models for human OTC deficiency we have used to develop and evaluate adenoviral vectors for liver-directed gene therapy (7–10). In the two available models, point mutations lead to dysfunctional or reduced OTC enzyme protein resulting in metabolic and clinical abnormalities consistent with a partial deficiency in humans. The model used primarily in this study, the spf mouse, has an 85% reduction in liver OTC activity which leads to an activation of de novo pyrimidine synthesis as evidenced by a 13-fold increase in excretion of orotic acid in the urine (11). Nitrogen accumulates in these animals, as evidenced by a 60% increase in serum glutamine. Conversion of <sup>15</sup>NH<sub>4</sub><sup>+</sup> to urea is decreased to 50% of
control, and the level of serum citrulline, a urea cycle intermediate, is decreased to 25% of control (11).

An E1-deleted adenoviral vector was constructed that contains human OTC cDNA (referred to as a first generation virus) expressed from a CMV-enhanced β-actin promoter. Pilot experiments were performed to determine the dose of virus necessary to increase OTC enzyme activity significantly in liver when vector was infused into spf mice. We found that the maximally tolerated dose of a first generation virus containing human OTC (i.e. 5 x 10^{11} particles) resulted in only a modest increase in OTC activity over baseline. This represents 5-fold more virus than what is necessary to transduce 80% of hepatocytes based on experiments with similar vectors expressing a variety of reporter genes (13, 15, 31). A histochemical stain for OTC activity was used to better characterize the distribution and level of OTC expression (Fig. 2). The specificity of this assay was demonstrated in analyses of C3H animals (Fig. 2A), which show a dark brown reaction product in 100% of cells that was absent in spf hemizygotes (Fig. 2C); heterozygotes show two populations of OTC-expressing cells consistent with lyonization of the x-chromosome (Fig. 2B). Histochemical analysis of spf liver removed 4 days after infusion of 5 x 10^{11} particles of first generation human OTC vector was underwhelming with expression detected at low levels in most cells (Fig. 2D), diminishing to baseline by days 7–14 (Fig. 2, E and F), concurrent with the development of substantial but self-limited hepatitis (Fig. 3A). Not surprising, there was no significant change in either urinary orotate (Fig. 4A) or serum glutamine (data not shown) when compared to animals that received identical doses of lacZ virus; urinary orotate nonspecifically decreased to approximately 50% of pretreatment levels with both viruses, possibly due to the associated hepatitis.

The relatively poor performance of the E1-deleted vector was felt to be, in part, due to the inherent immunogenicity of first generation constructs. We described in other systems that E1-deleted viruses express viral genes whose proteins are targets for destructive cellular immune responses (13, 18, 20, 31). Our first attempt to improve E1-deleted adenoviral vectors, by inactivating the essential gene product of E2a with a temperature-sensitive mutation, has shown promise in mouse liver, and mouse, rat, and primate lung, using lacZ-containing constructs (19, 31–33). In each case, expression of the transgene is prolonged for a variable period of time and associated with diminished inflammation. A second generation vector was constructed that was deleted in E1, defective in E2a due to the ts125 mutation, and contained a human OTC cDNA minigene. As expected, the levels of viral late gene RNA (Fig. 5A, lanes 1 and 2) and protein (Fig. 6, A and B) are diminished over that observed with the E1-deleted virus; the associated hepatitis is also decreased (Fig. 3A). Expression of the human OTC cDNA is still low; however, it appears slightly more stable (Fig. 2, G-I) from what is observed with the E1-deleted virus (Fig. 2, D-F). A nonspecific decrease (–50% of pretreatment levels) in urine orotate (Fig. 4B) and nonsignificant increase in serum glutamine (Fig. 4C) were again found in animals treated with either the lacZ or OTC virus. We concluded from these experiments that E1-deleted adenoviral vectors containing human OTC cDNA driven by the CMV-enhanced β-actin promoter were inadequate for gene therapy in the spf mouse, and the benefit of incorporating the ts125 mutation was minimal.

Efficient Expression of OTC from Adenoviral Vectors with Strong Constitutive Promoters and Species-homologous cDNAs— The most striking aspect of the studies presented above is the paucity of OTC expression achieved with the human OTC-based vectors and the lack of enhanced performance in vectors containing the ts125 mutation. This suggested problems with the human OTC cDNA functioning in the mouse model. Direct sequence analysis of viral DNA confirmed the structure of the human OTC minigene ruling out the trivial explanation of mutation or rearrangement (data not shown). Analysis of RNA from liver of treated animals revealed recombinant derived human OTC mRNA in excess of the level of endogenous OTC mRNA, supporting the hypothesis that greater expression of the therapeutic protein could be achieved in a vector that contains a stronger promoter and uses isogenic OTC cDNA. Differences in amino acid sequence between the OTC murine and human homologs may affect the ability of the human enzyme to fold, oligomerize, and/or traffic to the mitochondria where it can function. In fact, 10 of the 26 amino acid differences present between mouse and human OTC are located in the leader sequence. In addition, the human protein may be immunogenic in the mouse. To evaluate these hypotheses, first and second generation viruses were constructed in which human OTC cDNA was replaced with mouse OTC cDNA, and the CMV enhancer/chicken β-actin promoter (CB) was replaced with the strong constitutive viral enhancer/promoter from CMV.
First generation vectors that differed by the promoter, the OTC cDNA, or both were constructed and infused into spf mice. Liver tissue was harvested 3 days later and analyzed for OTC activity by lysate enzyme analysis (Fig. 7). The original vector expressing human OTC from the CMV/β-actin promoter produced little enzyme activity above background in spf liver. A 3-fold increase in activity was achieved when the CMV promoter/enhancer was used to express the human OTC cDNA. An additional 2- to 3-fold increase was realized when the human OTC cDNA was replaced with the murine homolog in the CMV-based vector.

Metabolic Correction Is Complete and Prolonged in spf Mice Treated with E2a-defective Adenoviral Vectors Containing Mouse OTC cDNA—Gene therapy experiments were repeated with first and second generation versions of the vector expressing mouse OTC cDNA from the CMV promoter. The first generation mouse OTC cDNA vector was infused into spf mice, and lysates of liver harvested 3 days after gene transfer were analyzed for expression of OTC activity. OTC activity was normalized with a dose of mouse OTC virus that was 2-5-fold less than the maximally tolerated dose of human OTC virus that only partially corrected OTC deficiency. Histochemical analysis demonstrated OTC activity in the majority of hepatocytes of spf animals treated with mouse OTC virus (Fig. 2). Transgene expression diminished with time, although OTC activity was detected in at least one-third of hepatocytes at day 28 (Fig. 2L). Urinary orotate decreased to 10% of pretreatment levels by day 7 and gradually returned to baseline by day 42 (Fig. 8A). Correction of urinary orotate was significantly greater than the nonspecific reduction seen with the lacZ virus, although it was not complete. A 30% decline in serum glutamine was measured with the most substantial improvement, realized 20 days after gene transfer, approaching normal levels, thereafter returning to baseline within 42 days of gene transfer (Fig. 8B).

Experiments were repeated with the second generation virus in which the ts125 mutation in E2a was introduced into the E1-deleted vector containing the mouse OTC minigene. This vector performed substantially better in all categories in comparison to the corresponding first generation construct. Expression of OTC enzyme as measured by the histochemical stain was higher (Fig. 2M) and prolonged (Fig. 2, N and O). Inflammation was reduced (Fig. 3B), as was expression of late viral genes at the level of RNA (Fig. 5A, lanes 3 and 4) and protein (Fig. 6, C and D). Abnormalities in urine orotate and glutamine were completely normalized within 2–3 weeks of gene transfer; both metabolic parameters gradually returned to
baseline levels but remained significantly improved as compared to animals infused with lacZ virus for 2–3 months (Fig. 8A and B). A similar correction of urine orotate and serum glutamine was achieved in the other murine model of OTC deficiency, the spfash mouse, following infusion of second generation vector containing mouse OTC cDNA (Fig. 8, C and D).

Relationship between Genetic Complementation and Metabolic Correction—Previous studies in mice and humans deficient in OTC suggested reconstitution of OTC in liver should be sufficient for some level of metabolic correction. Several lines of transgenic mice have been established that express normal OTC cDNA in the murine models genetically deficient in OTC. Introduction of a minigene expressing rat OTC cDNA from an SV40 promoter into the germ line of spfash mice resulted in phenotype conversion as evidenced by normal hair growth and diminished excretion of orotic acid (34). OTC activity was increased to 80–90% of control in both liver and intestine. A similar approach was taken by Jones et al. (35) in spf mice with
a construct carrying human OTC cDNA under control of the mouse OTC promoter. Two transgenic hemizygous males demonstrated normal fur and orotic acid excretion. Interestingly, these animals expressed high levels of the transgene in intestine but low levels in liver. Both studies implicate an important role of OTC expression in bowel and/or liver although neither measured the impact of gene transfer on serum amino acids which should represent more directly urea cycle function.

Our study demonstrates complete correction of orotic acid overproduction following hepatic reconstitution of OTC in both the spf and spf ash mouse. We also measured the impact of gene therapy on serum amino acids and showed a normalization of serum glutamine reflecting a decrease in nitrogen stores. It was interesting that in the case of the first generation, murine OTC vector, correction of serum glutamine lagged behind biochemical correction of enzyme activity and the peak reduction in urine orotate. The reason for this is unclear; however, we speculate it may be due to the combined effects of increased OTC enzyme expression with the superimposed but transient decline in liver function that occurs because of adenovirus-induced hepatitis. The relative impact of gene therapy on various metabolic parameters will be determined by the balance of gene correction versus liver injury.

Despite normalizing serum glutamine and urine orotic acid, adenovirus-mediated gene transfer did not significantly impact on depleted serum citrulline (data not shown). This is consistent with the experience of orthotopic liver transplantation in carbamyl-phosphate synthetase and OTC deficiencies that all serum amino acids are corrected except citrulline which remains low (6, 36). One explanation is that serum citrulline is primarily contributed to by extrahepatic nitrogen ureagenesis which is not corrected using liver-directed approaches. Through the action of a partial urea cycle in gut, including OTC, glutamine nitrogen is converted to citrulline which is transported via the blood to kidney, where it is converted to arginine. The role of this extrahepatic pathway in humans appears minor as suggested by the observation that transplant recipients realize substantially improved tolerance to nitrogen challenges despite maintaining low serum citrulline levels (36).
Implications for Gene Therapy of Liver Metabolic Diseases—This study systematically evaluated the impact of both the transgene and vector on the safety and efficiency of adenovirus-mediated gene transfer to liver. Vectors containing human OTC cDNA did not function as well in mouse liver as did the corresponding murine OTC constructs. One explanation is that the human OTC protein is not properly processed in a mouse cell to form catalytically active, mitochondrial-localized enzyme. Another explanation for the apparent dysfunction of the human OTC cDNA is that its protein is viewed as a neoantigen in the spf mouse eliciting confounding and destructive immune responses. Analysis of mice infected with human OTC adenovirus detected cytotoxic T cells but not antibodies to human OTC protein (data not shown). While primary antigen-specific cellular immune responses may decrease stability of transgene expression at day 7 and beyond, they cannot limit efficiency at early time points such as day 3.

Previous studies have clearly implicated cellular immunity in the loss of transgene expression and associated inflammation that has characterized E1-deleted adenoviruses (18–20, 37). Both T helper cells of the TH1 subset and CTLs are necessary for the observed destabilization of transgene expression. TH1 cells are activated to the input viral capsid proteins in a class II-dependent manner, while CTLs are activated to newly synthesized peptides presented by class I major histocompatibility complex. Viral proteins expressed from intact open reading frames in the recombinant virus as well as the transgene product itself are potential targets of CTL. It has been difficult quantifying the relative contribution of viral versus transgene

| Mouse | Virus injected | OTC activity (umol citrulline/mg protein/h) |
|-------|----------------|------------------------------------------|
| spf   | H5.010CBhOTC   | 0 100 200 300 400                        |
| spf   | H5.010CMVhOTC  | 0 100 200 300 400                        |
| spf   | H5.010CMVmOTC  | 0 100 200 300 400                        |
| spf   | H5.010CMVlacZ  | 0 100 200 300 400                        |
| C3H   | None           | 0 100 200 300 400                        |

**Fig. 7.** Liver OTC activity in spf mice infused with recombinant adenovirus. spf mice were infused with 2 × 10¹¹ particles of recombinant adenovirus and sacrificed at day 3 postinfusion. Data are presented as OTC activity (umol of citrulline/mg of protein/h) in mice (spf or C3H) inoculated with a variety of vectors. OTC activity in liver tissue was determined as described under "Experimental Procedures."

**Fig. 8.** Urinary orotate excretion and plasma glutamine levels in spf and spf⁺⁺⁺⁺ mice infused with recombinant adenoviruses carrying mouse OTC cDNA. spf/y mice (A and B) at 6–8 weeks of age were infused with 2 × 10¹¹ particles of first-generation (H5.010CMVmOTC) or second-generation virus (H5.110CMVmOTC or H5.110CMVlacZ) through tail vein. spf+/y mice (C and D) of similar age were infused with 2 × 10¹¹ particles of the second-generation viruses (H5.110CMVmOTC). Urine and plasma samples were collected at day −3, day −1, and at weekly intervals after virus infusion. Urinary orotate levels were measured in duplicate for each sample. Urinary orotating of creatinine are presented as a percent of pretreatment levels and are the mean ± S.E. of at least 4 determinations. Plasma glutamine levels were determined as described previously by Robinson et al. (29). The levels are presented as a percent of pretreatment levels and are the mean ± S.E. of between 4 and 10 determinations.
protein to activation of destructive cellular immune responses. Most experiments have used transgenes whose protein products are easily distinguished from endogenous protein but which run the risk of being neoantigens (e.g. lacZ, luciferase, chloramphenicol acetyltransferase, etc.) Previous experiments with E1-deleted viruses containing lacZ demonstrated CTLs to both viral proteins and Escherichia coli β-galactosidase; however, adaptive transfer experiments indicated immune responses to viral antigens from β1-deleted viruses are sufficient to ablate transgene expression (38).

Characterization of the performance of adenoviral vectors containing normal mouse OTC cDNA provides an opportunity to evaluate directly the relative contribution of viral protein versus transgene product in eliciting destabilizing cellular immunity. This is the first example in which adenovirus-mediated gene transfer has been performed with a transgene whose product should not be viewed as a neoantigen; transgene-derived OTC differs by only one amino acid from the spf OTC, and is identical with the product of the spf $^{a 1 h}$ allele. Transgene expression with the mouse OTC cDNA vectors persisted longer than what we have consistently observed with vectors expressing non-self transgenes such as β-galactosidase. Incorporating the ts125 mutation into this vector diminished late viral gene expression and further prolonged transgene expression. However, even under optimal conditions of isogenic OTC cDNA in a second generation virus, the expression of transgene eventually diminished to undetectable levels within 3–4 months of gene transfer. This is less stable than what has been observed when E1-deleted lacZ viruses are infused into athymic or Rag2 knockout mice (data not shown and Refs. 18 and 20). Eliminating antigenicity of the transgene product will not be sufficient to prevent all destructive cellular immune responses.

Our data in the authentic animal models of OTC deficiency support the utility of recombinant adenoviruses for treating liver metabolic diseases. Complete and prolonged correction of the metabolic defect has been demonstrated following a single infusion of purified virus. Current limitations of the technology are the potential of CTL responses to residual expressed viral protein and possibly to OTC in patients with null mutations. In addition, previous studies have described the development of neutralizing antibodies to input viral proteins that block gene transfer upon second administration (13). Improved vectors may diminish CTL to viral protein but will have no effect on neutralizing antibody to capsid protein or CTL to OTC. Activation of CD4 T helper cells to input viral proteins is necessary for both B cell and CTL activation (37). Transient blockade of the initial CD4 T cell activation at the time of virus instillation has been shown to both prolong transgene expression and prevent formation of neutralizing antibody (39). This suggests a strategy for treating OTC deficiency based on coadministration of an immune modulator together with an improved recombinant adenovirus.

Acknowledgments—We thank Antoneta Radu for preparing tissue sections and helping us with the histochemical staining of OTC activity. We also thank Carol Pabin and Rebecca Brown for their technical assistance with the analysis of urinary orotate and plasma amino acid.

REFERENCES

1. Nagata, N., Matsuda, I., and Oyanagi, K. (1991) Am. J. Med. Genet. 39, 228–229
2. Batshaw, M. L., Brusilow, S., Biber, L., Blom, W., Brubakk, A. M., Burton, B. K., Cann, H. M., Kerr, D., Mamunes, P., Matalon, R., Myerberg, D., and Schafer, I. A. (1982) N. Engl. J. Med. 306, 1387–1392
3. Brusilow, S. W., and Horwich, A. L. (1995) In The Molecular and Cellular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds) Vol. 1, pp. 1187–1232, McGraw-Hill, New York
4. Broelsch, C. E., Emond, J. C., Whitlington, P. F., Thistlethwaite, J. R., Baker, A. L., and Lictor, J. L. (1990) Ann. Surg. 212, 368–377
5. Todo, S., Starzl, T. E., Tzakis, A., Benkov, K. J., Kalousek, F., Sahi, T., Tanikawa, K., and Fenton, W. A. (1990) Hepatology (Baltimore) 15, 419–422
6. Largilliere, C., Housin, D., Gottrand, F., Mathey, C., Checoury, A., Alagille, D., and Fariaux, J. (1989) J. Pediatr. 115, 415–417
7. Veres, G., Gibis, R. A., Scherer, S. E., and Caskey, C. T. (1987) Science 237, 415–417
8. Qureshi, I. A., Letarte, J., and Ouellet, R. (1979) Pediatr. Res. 13, 807–811
9. Doolittle, R. F., Konigsberg, W., and Rosenberg, L. E. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 389–393
10. Hodges, P. E., and Rosenberg, L. E. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 4342–4346
11. Batshaw, M. L., Yudoff, M., McLaughlin, B., Gorry, E., Anegawa, N. J., Smith, I. A., Hyman, S. L., and Robinson, M. B. (1995) Gene Ther. 2, 743–749
12. Herz, J., and Gerard, R. D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2812–2816
13. Korsakov, K., McKinley, D. P., Huber, S., and Farriaux, J. (1989) J. Biol. Chem. 264, 1217–1229
14. Stratford-Perricaudet, L. D., Levrero, M., Chasse, J. F., Perricaudet, M., and Briand, P. (1990) Human Gene Ther. 1, 241–256
15. Morsy, M., Alford, E., Bett, A., Graham, F., and Caskey, C. (1993) J. Clin. Invest. 92, 883–893
16. Li, Q., Kay, M., Finegold, M., Stratford-Perricaudet, L., and Woo, S. (1993) Human Gene Ther. 4, 403–409
17. Yang, Y., Nunes, F., Benecski, C., Forth, E., Gonzalez, E., and Wilson, J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4407–4411
18. Yang, Y., Ertti, H., and Wilson, J. (1994) Immunity 1, 433–442
19. Cronnehlome, T. M., and Bianchi, D. W. (1994) Semin. Perinatol. 18, 376–384
20. Horwich, A. L., Fenton, W. A., Williams, K. R., Kalousek, F., Kraus, J. P., Doolittle, R. F., Konigsberg, W., and Rosenberg, L. E. (1984) Science 224, 1068–1074
21. Grossman, M., Raper, S., and Wilson, J. (1992) Human Gene Ther. 3, 501–510
22. Ensinger, M. J., and Ginsberg, H. S. (1972) J. Virol. 10, 328–339
23. Lee, J. T., and Nussbaum, R. L. (1989) J. Clin. Invest. 84, 1762–1766
24. Mizutani, A. (1968) J. Histochem. Cytochem. 16, 172–180
25. Brusilow, S. W., and Hauser, E. (1989) J. Chromatogr. 493, 388–391
26. Robinson, M. B., Dzial, S., and Bucalater, J. R. (1993) J. Neurochem. 61, 2099–2103
27. Kodolka, R., Ishak, K., Black, W., Chen, T., Craig, R., Kaplowitz, N., Kiernan, T., and Wollman, J. (1981) Hepatology (Baltimore) 1, 431–435
28. Engelhardt, J., Ye, X., Doranz, B., and Wilson, J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 6196–6200
29. Engelhardt, J., Lesky, L., and Wilson, J. (1994) Human Gene Ther. 5, 1217–1229
30. Goldman, M. J., Lesky, L., Engelhardt, J. F., and Wilson, J. M. (1995) Human Gene Ther. 6, 839–851
31. Cavadar, C., Grimmer, G., Dubois, N., Chasse, J., Bennou, M., Minet-Thuriaux, M., Kamoun, P., and Briand, P. (1988) Nucl. Acids Res. 16, 2099–2110
32. Jönsson, S. N., Grompe, M., Munir, M. I., Veres, G., and Caskey, C. T. (1990) J. Biol. Chem. 265, 1484–1469
33. Tuchman, M. (1989) N. Engl. J. Med. 320, 1498–1499
34. Yang, Y., Yang, M., Ertti, H., and Wilson, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7277–7281
35. Yang, Y., Joss, K. U., Su, Q., Ertti, H. C. J., and Wilson, J. M. (1996) Gene Ther. in press
36. Yang, Y., Trinchieri, G., and Wilson, J. M. (1995) Nature Med. 1, 890–893
Prolonged Metabolic Correction in Adult Ornithine Transcarbamylase-deficient Mice with Adenoviral Vectors
Xuehai Ye, Michael B. Robinson, Mark L. Batshaw, Emma E. Furth, Ian Smith and James M. Wilson

J. Biol. Chem. 1996, 271:3639-3646.
doi: 10.1074/jbc.271.7.3639

Access the most updated version of this article at http://www.jbc.org/content/271/7/3639

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 38 references, 11 of which can be accessed free at http://www.jbc.org/content/271/7/3639.full.html#ref-list-1